WALTHAM, Mass., July 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it will present at the upcoming JMP Securities Healthcare Conference on Friday, July 13, 2012 at 11:30 a.m. Eastern Time. Eric Bouvier, President and CEO of the Company, will present an overview of BG Medicine. The corporate presentation will be available to the public through a webcast accessible by visiting: http://wsw.com/webcast/jmp18/bgmd/ or the "Investors" section of the Company's website at www.bg-medicine.com. Replays will be available for 30 days after the presentation.
About BG Medicine, Inc.
BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
Michael W. Rogers EVP & Chief Financial Officer (781) 890-1199